What role does the DPP-4 inhibitor Trajenta® (linagliptin) have in improving outcomes in type 2 diabetes in older adults? Examining complex case studies

For healthcare professionals only.

A Boehringer Ingelheim promotional webinar
Wednesday 22 September - 19:00 - 20:00

Click here for prescribing information and adverse event reporting for GB and NI

REGISTER HERE

We are pleased to invite you to a webinar organised by Boehringer Ingelheim in collaboration with DPC, taking place on Wednesday 22 September at 7pm. This educational webinar is CPD certified and free to attend.

Although the elderly and frail are at increased risk of developing type 2 diabetes (1), the presence of comorbidities and polypharmacy may potentially limit medication choices in this population (2).

Some national and international guidelines recommend dipeptidyl peptidase-4 (DPP-4) inhibitors as a suitable treatment option for adults with type 2 diabetes at various stages of disease progression (3-5). This session will use practical (fictitious and hypothetical) case study examples to examine situations where it may be appropriate to prescribe the DPP-4 inhibitor Trajenta® (linagliptin).

SESSION SPEAKERS:

• David Strain, Senior Clinical Lecturer at the University of Exeter Medical School, and Honorary Consultant in Medicine
• Su Down, Nurse Consultant Diabetes, Somerset Foundation Trust

LEARNING OUTCOMES:

• Understand the challenges associated with managing type 2 diabetes, particularly in the aging population
• Provide an overview of the current guideline recommendations for the management of older adults with type 2 diabetes
• Examine with the help of practical case studies (fictitious and hypothetical scenarios), the potential role and clinical data supporting the use of the DPP-4 inhibitor Trajenta® (linagliptin) in the treatment of older adults with type 2 diabetes

CLICK HERE TO REGISTER FOR FREE

This promotional webinar has been developed, organised and funded by Boehringer Ingelheim. The content has been reviewed and approved by the sponsoring company and the speakers prior to broadcast.

Boehringer Ingelheim products will be discussed during this presentation.
Prescribing information and adverse event reporting details for Trajenta® (linagliptin) are available at this meeting.

This webinar is eligible for 1 CPD point. 

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Boehringer Ingelheim Drug Safety on 0800 328 1627 (freephone).

1. NHS Digital. Diabetes prevention programme, 2017–18. Diagnoses and demographics. NHS Digital, 2019. Available at: files.digital.nhs.uk/1B/D8C0E4/NDA_DPP_MainReport_1718_1.1.pdf (accessed September 2021).
2. Strain WD et al. Diabet Med. 2018;35:838–845
3. NICE. Type 2 diabetes in adults: management. NICE Guideline 28. Available at: guidance.nice.org.uk/ng28 (accessed September 2021)
4. SIGN 154. Pharmacological management of glycaemic control in people with type 2 diabetes. November 2017. Available at: www.sign.ac.uk (accessed September 2021)
5. Davies MJ et al. Diabetologia. 2018;61:2461–2498
   

Date of Preparation September 2021 | PC-GB-105510